ClinicalTrials.gg
CompletedNCT03895203BE OPTIMALUpdated Sep 28, 2026Results posted

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

A Phase 3 interventional study of Bimekizumab and Adalimumab in Psoriatic Arthritis, sponsored by UCB Biopharma SRL. Completed at 136 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Sep 28, 2026Results publication addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
852
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.

Enrollment
2nd of 14
852 · median 210
Started
2019
with 3 others
Phase 3
8 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
10 of 14
UCB Biopharma SRL

Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 2nd largest by enrollment, is one of 4 that started in 2019, is one of 8 in phase 3, and was the 7th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bimekizumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriatic Arthritis
  • PsA
  • Bimekizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written form is signed and dated by the subject
  • Subject is male or female at least 18 years of age
  • Female subject must be , permanently sterilized or willing to use a highly effective method of
  • Documented diagnosis of adult-onset Psoriatic Arthritis (PsA) meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) for at least 6 months prior to Screening with active PsA and must have at Baseline tender joint count (TJC) >=3 out of 68 and swollen joint count (SJC) >=3 out of 66
  • Subject must be negative for rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies
  • Subject must have at least 1 active psoriatic lesion(s) and/or a documented history of psoriasis (PSO)
  • Subject must be a suitable candidate for treatment with adalimumab and has no to receive adalimumab as per the local label as assessed by the Investigator
  • Subjects currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics (including mild opioids), , methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study
  • Subjects with current or prior exposure to any biologics for the treatment of Psoriatic Arthritis (PsA) or Psoriasis (PSO)
  • Subject has an active infection or a history of recent serious infections
  • Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
  • Subject has a diagnosis of inflammatory conditions other than PSO or PsA. Subjects with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease at Screening or Baseline
  • Subject had acute anterior uveitis within 6 weeks of Baseline
  • Subject has any active or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
  • Subject has a form of PSO other than chronic plaque-type (eg, pustular, erythrodermic and guttate PSO, or drug-induced PSO)
  • Presence of active suicidal ideation, or moderately severe major depression or severe major depression
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
852 participants (actual)

Study arms

  • Experimental
    Bimekzumab dosage regimen

    Subjects randomized to this arm will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.

    Drug: Bimekizumab · Other: Placebo

  • Active comparator
    Adalimumab dosage regimen

    Subjects randomized to this arm will receive the assigned adalimumab dosage regimen during the Treatment Period.

    Drug: Adalimumab

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be reallocated to receive bimekizumab dosage regimen during the Maintenance Period.

    Drug: Bimekizumab · Other: Placebo

Interventions

  • Subjects will receive bimekizumab at pre-specified time-points.

    Also known as: BKZ, UCB4940

  • Adalimumab will be administered according to the labeling recommendations.

    Also known as: HUMIRA®

  • OtherPlacebo

    Subjects will receive placebo at pre-specified time-points.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16

    ACR50 response rate: 50% or greater improvement of arthritis relative to Baseline. Those who met following 3 conditions for improvement from Baseline were classified as meeting ACR50 response criteria: greater than or equal (≥) 50% improvement in 68-tender joint count; ≥ 50% improvement in 66-swollen joint count; ≥ 50% improvement in at least 3 of 5 following parameters: Physician global assessment of disease activity (0-100 millimeter \[mm\] visual analog scale \[VAS\] \[0 = no symptoms;100 = severe symptoms\]), Patient global assessment of disease activity (100 mm VAS \[0 = no limitation of normal activities; 100 = very poor\]), Patient assessment of pain (100 mm VAS \[0 = no pain; 100 = most severe pain\]), Health Assessment Questionnaire-Disability Index (HAQ-DI) assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, lower scores indicated less disability and high-sensitivity C-reactive protein (hsCRP).

    Time frame: Week 16

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16 for Placebo and BKZ

    The HAQ-DI contains 20 items that measured the degree of difficulty experienced in the following 8 categories of the daily living activities: dressing and grooming (2 items), arising (2 items), eating (3 items), walking (2 items), hygiene (3 items), reach (2 items), grip (3 items), and common daily activities (3 items). Each question was scored 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do). The overall HAQ-DI total score was calculated by dividing the sum of the highest category scores (0 to 24) by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (no difficulty) to 3 (maximum difficulty). A lower HAQ-DI score indicated an improvement in function. Change from baseline was computed as the value at Week 16 minus the baseline value. A negative value in change from baseline indicated an improvement.

    Time frame: Baseline, Week 16

  2. Percentage of Participants With a Psoriasis Area Severity Index (PASI) 90 Response at Week 4 in the Subgroup of Participants With Psoriasis (PSO) Involving at Least 3% Body Surface Area (BSA) at Baseline

    The PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI = average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0 = no disease, the maximum score is 72 = maximal disease.

    Time frame: Baseline, Week 4

  3. Percentage of Participants With a PASI90 Response at Week 16 in the Subgroup of Participants With PSO Involving at Least 3% BSA at Baseline

    The PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI = average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0 = no disease, the maximum score is 72 = maximal disease.

    Time frame: Baseline, Week 16

  4. Change From Baseline in the Short Form 36-item Health Survey (SF-36) Physical Component Summary (PCS) at Week 16 for Placebo and BKZ

    SF-36 (version 2, standard recall):36-item generic health-related Quality of Life instrument that uses recall period of 4 weeks. Questionnaire has 36 questions composing scale that represent 8 domains:physical functioning; role physical; bodily pain;general health;vitality; social functioning;role emotional; and mental health. Scores for 8 domains were combined into two summary scores: physical component summary (PCS) score and mental component summary (MCS) score. Scores for 2 components summary (PCS and MCS) and 8 domains have been calculated and computed as raw/observed score to norm-based T-score metric(mean=50, standard deviation=10), raw score min=0(worst), max=100(best). Individual respondent's score falls outside T-score range of 45 to 55 was considered outside average range and when considering group-level data, score below 47 was considered indicative of impaired functioning within that health domain or dimension. Positive value in change from Baseline indicated improvement.

    Time frame: Baseline, Week 16

  5. Percentage of Participants With a Minimal Disease Activity (MDA) at Week 16

    MDA is measure to indicate disease remission, and is based on composite score of 7 domains. Participant is considered having achieved MDA if participant fulfills at least 5 of following 7 criteria: Tender joint count (0-68 joints) less than or equal to (≤1); Swollen joint count (0-66 joints) ≤ 1; PASI ≤ 1 or BSA ≤ 3: In PASI, body divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. Total score ranges from 0(no disease) to 72 (maximal disease)\]; Patient's Assessment of Arthritis Pain ≤ 15 \[using VAS on a scale of 0 (no pain) to 100 (severe pain)\]; Patient's Global Assessment of Disease Activity ≤ 20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤ 0.5, HAQ-DI score ranges from 0 (no difficulty) to 3 (maximum difficulty); Leeds Enthesitis Index score ≤ 1 for participants with enthesitis at baseline.

    Time frame: Week 16

  6. Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdHmTSS) in Participants With Elevated Hs-CRP and/or at Least 1 Bone Erosion at Baseline at Week 16 for Placebo and BKZ

    The degree of joint damage was assessed using the vdHmTSS by quantifying the extent of bone erosions and joint space narrowing for 64 and 52 joints, respectively. The vdHmTSS ranges from 0 to 528, with higher scores representing greater damage. Descriptive statistics for ADA 40 mg reference arm was not calculated and reported since reference based imputation analysis method is used with Placebo as reference. As pre-specified in the SAP, this analysis was performed only for the participants randomized to Placebo and BKZ.

    Time frame: Baseline, Week 16

  7. Percentage of Participants With an Enthesitis-free State in the Leeds Enthesitis Index (LEI) at Week 16 in the Subgroup of Participants With Enthesitis at Baseline in the Pooled Population of PA0010 and PA0011

    Presence of enthesitis was assessed in the subgroup of participants with enthesitis by palpation on the lateral epicondyles of the humerus (elbows), medial femoral epicondyles (knees), and Achilles tendons (heels) bilaterally and scored as 0 (no tenderness) and 1 (tenderness) at Baseline. The LEI consists of 6 items, 3 for the right part and 3 for the left part of the body. LEI is derived as the sum of the enthesitis score over the 6 sites mentioned above. The total score ranges from 0 to 6, higher scores indicates greater degree of enthesitis. Descriptive/Inferential statistics for ADA 40 mg reference arm was not calculated and reported since pooled data with PA0011 study is used which did not have ADA 40 mg arm.

    Time frame: Baseline of PA0010 for Participants of PA0010 and Baseline of PA0011 for Participants of PA0011, Week 16

  8. Percentage of Participants With a Dactylitis-free State Based on the Leeds Dactylitis Index (LDI) at Week 16 in the Subgroup of Participants With Dactylitis at Baseline in the Pooled Population of PA0010 and PA0011

    The LDI quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot). The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI score. A higher LDI indicates worse dactylitis. Tenderness score (0 = no tenderness, 1 = tender). Descriptive/Inferential statistics for ADA 40 mg reference arm was not calculated and reported since pooled data with PA0011 study was used which did not have ADA 40 mg arm.

    Time frame: Baseline of PA0010 for Participants of PA0010 and Baseline of PA0011 for Participants of PA0011, Week 16

  9. Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 16

    The ACR20 response rate was based on a 20% or greater improvement of arthritis relative to Baseline. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: Physician global assessment of disease activity (100 mm VAS \[0 = no symptoms; 100 = severe symptoms\]), Patient global assessment of disease activity (100 mm VAS \[0 = no limitation of normal activities; 100 = very poor\]), Patient assessment of pain (100 mm VAS \[0 = no pain; 100 = most severe pain\]), HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, lower scores indicated less disability, hsCRP.

    Time frame: Week 16

  10. Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdHmTSS) in the Overall Population at Week 16 for Placebo and BKZ

    The degree of joint damage was assessed using the vdHmTSS by quantifying the extent of bone erosions and joint space narrowing for 64 and 52 joints, respectively. The vdHmTSS ranges from 0 to 448, with higher scores representing greater damage. Descriptive statistics for ADA 40 mg reference arm was not calculated and reported since reference based imputation analysis method was used with Placebo as reference.

    Time frame: Baseline, Week 16

  11. Percentage of Participants With an American College of Rheumatology (ACR) 70 Response at Week 16

    The ACR70 response rate was based on a 70% or greater improvement of arthritis relative to Baseline. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: Physician global assessment of disease activity (100 mm VAS \[0 = no symptoms;100 = severe symptoms\]), Patient global assessment of disease activity (100 mm VAS \[0 = no limitation of normal activities;100 = very poor\]), Patient assessment of pain (100 mm VAS \[0 = no pain; 100 = most severe pain\]), HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, lower scores indicated less disability, hsCRP.

    Time frame: Week 16

  12. Percentage of Participants With Investigator Global Assessment (IGA) Response Defined as Score of 0 (Clear) or 1 (Almost Clear) AND at Least a 2-grade Reduction From Baseline at Week 4 in the Subset of Participants With Psoriatic Skin Lesions at Baseline

    IGA measured the overall severity of PSO using the following 5-point scale and score was rated as 0 = clear (No signs of PSO; post-inflammatory hyperpigmentation may be present), 1 = almost clear (No thickening; normal to pink coloration; no to minimal focal scaling), 2 = mild (Just detectable to mild thickening; pink to light red coloration; predominately fine scaling), 3 = moderate (Clearly distinguishable to moderate thickening; dull to bright red, moderate scaling), and 4 = severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). The IGA response is defined as score of 0 (clear) or 1 (almost clear) with at least a 2-category improvement relative to Baseline.

    Time frame: Baseline, Week 4

  13. Percentage of Participants With an IGA Response Defined as Score of 0 (Clear) or 1 (Almost Clear) AND at Least a 2-grade Reduction From Baseline at Week 16 in the Subset of Participants With Psoriatic Skin Lesions at Baseline

    IGA measured the overall severity of PSO using the following 5-point scale and score was rated as 0 = clear (No signs of PSO; post-inflammatory hyperpigmentation may be present), 1 = almost clear (No thickening; normal to pink coloration; no to minimal focal scaling), 2 = mild (Just detectable to mild thickening; pink to light red coloration; predominately fine scaling), 3 = moderate (Clearly distinguishable to moderate thickening; dull to bright red, moderate scaling), and 4 = severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). The IGA response is defined as score of 0 (clear) or 1 (almost clear) with at least a 2-category improvement relative to Baseline.

    Time frame: Baseline, Week 16

  14. Change From Baseline in the Patient's Assessment of Arthritis Pain (PtAAP) at Week 16

    The PtAAP VAS is part of the American College of Rheumatology core set of measures in arthritis. Participants assessed their arthritis pain using a VAS ranging from 0 (no pain) to 100 (most severe pain). A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 16

  15. Percentage of Participants With an Enthesitis-free State Based on the Spondyloarthritis Research Consortium of Canada (SPARCC) Index at Week 16 in the Subgroup of Participants With Enthesitis at Baseline

    Presence of enthesitis was assessed in the subgroup of participants with enthesitis at Baseline. The SPARCC index measures the severity of enthesitis through the assessment of 16 sites, 8 for the right part and 8 for the left part of the body: the greater trochanter (right/left), quadriceps tendon insertion into the patella (right/left), patellar ligament insertion into the patella and tibial tuberosity (right/left), achilles tendon insertion (right/left), plantar fascia insertion (right/left), medial and lateral epicondyles (right/left), and the supraspinatus insertion (right/left). Tenderness on examination is recorded as either present (1) or absent (0) for each of the 16 sites, for an average range of 0 (no enthesitis) to 16 (severe enthesitis).

    Time frame: Baseline, Week 16

  16. Change From Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Total Score at Week 16

    The PsAID-12 is a patient-reported outcome measure for assessing the impact of Psoriatic Arthritis (PsA) in 12 physical and psychological domains, including pain, fatigue, skin problems, work and/or leisure activities, functional capacity, discomfort, sleep disturbance, coping, anxiety/fear/uncertainty, embarrassment and/or shame, social participation, and depression. Each domain is assessed with a single question using a 0 to 10 numerical rating scale. Each domain score was multiplied by a weighting factor and the results were then summed to provide the total score. The total score ranged from 0 to 10, with higher scores indicating a worse status. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 16

  17. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs were defined as any AEs with an onset date on or after the date of first IMP administration and within 140 days after the final dose of IMP.

    Time frame: From Baseline until Safety Follow-Up (up to Week 72)

  18. Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

    A SAE is any untoward medical occurrence that at any dose: Results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization; is a congenital anomaly or birth defect; is an infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. TEAEs were defined as any AEs with an onset date on or after the date of first IMP administration and within 140 days after the final dose of IMP.

    Time frame: From Baseline until Safety Follow-Up (up to Week 72)

  19. Percentage of Participants With TEAEs Leading to Withdrawal From IMP During the Study

    An AE is any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs were defined as any AEs with an onset date on or after the date of first IMP administration and within 140 days after the final dose of IMP.

    Time frame: From Baseline until Safety Follow-Up (up to Week 72)

07

Results

Posted Oct 23, 2024

Participant flow

The study started to enroll participants in April 2019 and concluded in July 2022.

Double-Blind Treatment Period: 16 Weeks
Participant flow — Double-Blind Treatment Period: 16 Weeks
MilestonePlaceboBKZ 160 mg Q4WADA 40 mg Q2WPlacebo/BKZ 160 mg Q4WBKZ 160 mg Q4W/BKZ 160 mg Q4WADA 40 mg Q2W/ADA 40 mg Q2W
Started281431140000
Enthesitis at baseline: pa0010/pa0011 pooled population1062490000
Dactylitis at baseline: pa0010/pa0011 pooled population47900000
Completed271415137000
Not completed10163000
Withdrew: Adverse event282000
Withdrew: Lack of efficacy200000
Withdrew: Lost to follow-up200000
Withdrew: Withdrawal by subject461000
Withdrew: Phq-9 score elevated010000
Withdrew: Site terminated010000
Active Treatment-Blind Period: 36 Weeks
Participant flow — Active Treatment-Blind Period: 36 Weeks
MilestonePlaceboBKZ 160 mg Q4WADA 40 mg Q2WPlacebo/BKZ 160 mg Q4WBKZ 160 mg Q4W/BKZ 160 mg Q4WADA 40 mg Q2W/ADA 40 mg Q2W
Started000271414136
Completed000257387125
Not completed000142711
Withdrew: Death000100
Withdrew: Adverse event000594
Withdrew: Lack of efficacy000164
Withdrew: Lost to follow-up000130
Withdrew: Withdrawal by subject000492
Withdrew: Covid-19 pandemic circumstances000100
Withdrew: Withdrawal due to subject decision000100
Withdrew: Subject moving out of area000001

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16

ACR50 response rate: 50% or greater improvement of arthritis relative to Baseline. Those who met following 3 conditions for improvement from Baseline were classified as meeting ACR50 response criteria: greater than or equal (≥) 50% improvement in 68-tender joint count; ≥ 50% improvement in 66-swollen joint count; ≥ 50% improvement in at least 3 of 5 following parameters: Physician global assessment of disease activity (0-100 millimeter \[mm\] visual analog scale \[VAS\] \[0 = no symptoms;100 = severe symptoms\]), Patient global assessment of disease activity (100 mm VAS \[0 = no limitation of normal activities; 100 = very poor\]), Patient assessment of pain (100 mm VAS \[0 = no pain; 100 = most severe pain\]), Health Assessment Questionnaire-Disability Index (HAQ-DI) assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, lower scores indicated less disability and high-sensitivity C-reactive protein (hsCRP).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 1610.043.945.7
Statistical analysis
  • Placebo vs BKZ 160 mg Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.082 · 95% CI 4.583 to 10.943
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16 for Placebo and BKZ

The HAQ-DI contains 20 items that measured the degree of difficulty experienced in the following 8 categories of the daily living activities: dressing and grooming (2 items), arising (2 items), eating (3 items), walking (2 items), hygiene (3 items), reach (2 items), grip (3 items), and common daily activities (3 items). Each question was scored 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do). The overall HAQ-DI total score was calculated by dividing the sum of the highest category scores (0 to 24) by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (no difficulty) to 3 (maximum difficulty). A lower HAQ-DI score indicated an improvement in function. Change from baseline was computed as the value at Week 16 minus the baseline value. A negative value in change from baseline indicated an improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16 for Placebo and BKZ
score on a scalePlaceboBKZ 160 mg Q4W
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16 for Placebo and BKZ-0.0881 ± 0.0273-0.2567 ± 0.0208
Statistical analysis
  • Placebo vs BKZ 160 mg Q4W · ANCOVA · p = <0.001 · Least square (ls) mean difference: -0.187 · 95% CI -0.249 to -0.125
SecondaryPercentage of Participants With a Psoriasis Area Severity Index (PASI) 90 Response at Week 4 in the Subgroup of Participants With Psoriasis (PSO) Involving at Least 3% Body Surface Area (BSA) at Baseline

The PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI = average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0 = no disease, the maximum score is 72 = maximal disease.

Time frame:
Baseline, Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Area Severity Index (PASI) 90 Response at Week 4 in the Subgroup of Participants With Psoriasis (PSO) Involving at Least 3% Body Surface Area (BSA) at Baseline
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Percentage of Participants With a Psoriasis Area Severity Index (PASI) 90 Response at Week 4 in the Subgroup of Participants With Psoriasis (PSO) Involving at Least 3% Body Surface Area (BSA) at Baseline4.319.87.4
SecondaryPercentage of Participants With a PASI90 Response at Week 16 in the Subgroup of Participants With PSO Involving at Least 3% BSA at Baseline

The PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI = average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0 = no disease, the maximum score is 72 = maximal disease.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI90 Response at Week 16 in the Subgroup of Participants With PSO Involving at Least 3% BSA at Baseline
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Percentage of Participants With a PASI90 Response at Week 16 in the Subgroup of Participants With PSO Involving at Least 3% BSA at Baseline2.961.341.2
Statistical analysis
  • Placebo vs BKZ 160 mg Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 63.039 · 95% CI 22.211 to 178.918
SecondaryChange From Baseline in the Short Form 36-item Health Survey (SF-36) Physical Component Summary (PCS) at Week 16 for Placebo and BKZ

SF-36 (version 2, standard recall):36-item generic health-related Quality of Life instrument that uses recall period of 4 weeks. Questionnaire has 36 questions composing scale that represent 8 domains:physical functioning; role physical; bodily pain;general health;vitality; social functioning;role emotional; and mental health. Scores for 8 domains were combined into two summary scores: physical component summary (PCS) score and mental component summary (MCS) score. Scores for 2 components summary (PCS and MCS) and 8 domains have been calculated and computed as raw/observed score to norm-based T-score metric(mean=50, standard deviation=10), raw score min=0(worst), max=100(best). Individual respondent's score falls outside T-score range of 45 to 55 was considered outside average range and when considering group-level data, score below 47 was considered indicative of impaired functioning within that health domain or dimension. Positive value in change from Baseline indicated improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in the Short Form 36-item Health Survey (SF-36) Physical Component Summary (PCS) at Week 16 for Placebo and BKZ
score on a scalePlaceboBKZ 160 mg Q4W
Change From Baseline in the Short Form 36-item Health Survey (SF-36) Physical Component Summary (PCS) at Week 16 for Placebo and BKZ2.326 ± 0.4786.219 ± 0.402
Statistical analysis
  • Placebo vs BKZ 160 mg Q4W · ANCOVA · p = <0.001 · Ls mean difference: 4.337 · 95% CI 3.229 to 5.444
SecondaryPercentage of Participants With a Minimal Disease Activity (MDA) at Week 16

MDA is measure to indicate disease remission, and is based on composite score of 7 domains. Participant is considered having achieved MDA if participant fulfills at least 5 of following 7 criteria: Tender joint count (0-68 joints) less than or equal to (≤1); Swollen joint count (0-66 joints) ≤ 1; PASI ≤ 1 or BSA ≤ 3: In PASI, body divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. Total score ranges from 0(no disease) to 72 (maximal disease)\]; Patient's Assessment of Arthritis Pain ≤ 15 \[using VAS on a scale of 0 (no pain) to 100 (severe pain)\]; Patient's Global Assessment of Disease Activity ≤ 20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤ 0.5, HAQ-DI score ranges from 0 (no difficulty) to 3 (maximum difficulty); Leeds Enthesitis Index score ≤ 1 for participants with enthesitis at baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Minimal Disease Activity (MDA) at Week 16
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Percentage of Participants With a Minimal Disease Activity (MDA) at Week 1613.245.045.0
Statistical analysis
  • Placebo vs BKZ 160 mg Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.447 · 95% CI 3.668 to 8.088
SecondaryChange From Baseline in Van Der Heijde Modified Total Sharp Score (vdHmTSS) in Participants With Elevated Hs-CRP and/or at Least 1 Bone Erosion at Baseline at Week 16 for Placebo and BKZ

The degree of joint damage was assessed using the vdHmTSS by quantifying the extent of bone erosions and joint space narrowing for 64 and 52 joints, respectively. The vdHmTSS ranges from 0 to 528, with higher scores representing greater damage. Descriptive statistics for ADA 40 mg reference arm was not calculated and reported since reference based imputation analysis method is used with Placebo as reference. As pre-specified in the SAP, this analysis was performed only for the participants randomized to Placebo and BKZ.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdHmTSS) in Participants With Elevated Hs-CRP and/or at Least 1 Bone Erosion at Baseline at Week 16 for Placebo and BKZ
score on a scalePlaceboBKZ 160 mg Q4W
Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdHmTSS) in Participants With Elevated Hs-CRP and/or at Least 1 Bone Erosion at Baseline at Week 16 for Placebo and BKZ0.36 ± 0.100.04 ± 0.05
Statistical analysis
  • Placebo vs BKZ 160 mg Q4W · ANOVA · p = 0.001 · Ls mean difference: -0.327 · 95% CI -0.524 to -0.130
SecondaryPercentage of Participants With an Enthesitis-free State in the Leeds Enthesitis Index (LEI) at Week 16 in the Subgroup of Participants With Enthesitis at Baseline in the Pooled Population of PA0010 and PA0011

Presence of enthesitis was assessed in the subgroup of participants with enthesitis by palpation on the lateral epicondyles of the humerus (elbows), medial femoral epicondyles (knees), and Achilles tendons (heels) bilaterally and scored as 0 (no tenderness) and 1 (tenderness) at Baseline. The LEI consists of 6 items, 3 for the right part and 3 for the left part of the body. LEI is derived as the sum of the enthesitis score over the 6 sites mentioned above. The total score ranges from 0 to 6, higher scores indicates greater degree of enthesitis. Descriptive/Inferential statistics for ADA 40 mg reference arm was not calculated and reported since pooled data with PA0011 study is used which did not have ADA 40 mg arm.

Time frame:
Baseline of PA0010 for Participants of PA0010 and Baseline of PA0011 for Participants of PA0011, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Enthesitis-free State in the Leeds Enthesitis Index (LEI) at Week 16 in the Subgroup of Participants With Enthesitis at Baseline in the Pooled Population of PA0010 and PA0011
percentage of participantsPlaceboBKZ 160 mg Q4W
Percentage of Participants With an Enthesitis-free State in the Leeds Enthesitis Index (LEI) at Week 16 in the Subgroup of Participants With Enthesitis at Baseline in the Pooled Population of PA0010 and PA001134.949.8
Statistical analysis
  • Placebo vs BKZ 160 mg Q4W · Regression, Logistic · p = 0.008 · Odds ratio (or): 1.904 · 95% CI 1.180 to 3.074
SecondaryPercentage of Participants With a Dactylitis-free State Based on the Leeds Dactylitis Index (LDI) at Week 16 in the Subgroup of Participants With Dactylitis at Baseline in the Pooled Population of PA0010 and PA0011

The LDI quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot). The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI score. A higher LDI indicates worse dactylitis. Tenderness score (0 = no tenderness, 1 = tender). Descriptive/Inferential statistics for ADA 40 mg reference arm was not calculated and reported since pooled data with PA0011 study was used which did not have ADA 40 mg arm.

Time frame:
Baseline of PA0010 for Participants of PA0010 and Baseline of PA0011 for Participants of PA0011, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Dactylitis-free State Based on the Leeds Dactylitis Index (LDI) at Week 16 in the Subgroup of Participants With Dactylitis at Baseline in the Pooled Population of PA0010 and PA0011
percentage of participantsPlaceboBKZ 160 mg Q4W
Percentage of Participants With a Dactylitis-free State Based on the Leeds Dactylitis Index (LDI) at Week 16 in the Subgroup of Participants With Dactylitis at Baseline in the Pooled Population of PA0010 and PA001151.175.6
Statistical analysis
  • Placebo vs BKZ 160 mg Q4W · Regression, Logistic · p = 0.002 · Odds ratio (or): 3.437 · 95% CI 1.559 to 7.574
SecondaryPercentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 16

The ACR20 response rate was based on a 20% or greater improvement of arthritis relative to Baseline. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: Physician global assessment of disease activity (100 mm VAS \[0 = no symptoms; 100 = severe symptoms\]), Patient global assessment of disease activity (100 mm VAS \[0 = no limitation of normal activities; 100 = very poor\]), Patient assessment of pain (100 mm VAS \[0 = no pain; 100 = most severe pain\]), HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, lower scores indicated less disability, hsCRP.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 16
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 1623.862.268.6
SecondaryChange From Baseline in Van Der Heijde Modified Total Sharp Score (vdHmTSS) in the Overall Population at Week 16 for Placebo and BKZ

The degree of joint damage was assessed using the vdHmTSS by quantifying the extent of bone erosions and joint space narrowing for 64 and 52 joints, respectively. The vdHmTSS ranges from 0 to 448, with higher scores representing greater damage. Descriptive statistics for ADA 40 mg reference arm was not calculated and reported since reference based imputation analysis method was used with Placebo as reference.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdHmTSS) in the Overall Population at Week 16 for Placebo and BKZ
score on a scalePlaceboBKZ 160 mg Q4W
Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdHmTSS) in the Overall Population at Week 16 for Placebo and BKZ0.32 ± 0.090.04 ± 0.04
Statistical analysis
  • Placebo vs BKZ 160 mg Q4W · ANCOVA · p = 0.001 · Ls mean difference: -0.281 · 95% CI -0.452 to -0.111
SecondaryPercentage of Participants With an American College of Rheumatology (ACR) 70 Response at Week 16

The ACR70 response rate was based on a 70% or greater improvement of arthritis relative to Baseline. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: Physician global assessment of disease activity (100 mm VAS \[0 = no symptoms;100 = severe symptoms\]), Patient global assessment of disease activity (100 mm VAS \[0 = no limitation of normal activities;100 = very poor\]), Patient assessment of pain (100 mm VAS \[0 = no pain; 100 = most severe pain\]), HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, lower scores indicated less disability, hsCRP.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 70 Response at Week 16
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Percentage of Participants With an American College of Rheumatology (ACR) 70 Response at Week 164.324.427.9
SecondaryPercentage of Participants With Investigator Global Assessment (IGA) Response Defined as Score of 0 (Clear) or 1 (Almost Clear) AND at Least a 2-grade Reduction From Baseline at Week 4 in the Subset of Participants With Psoriatic Skin Lesions at Baseline

IGA measured the overall severity of PSO using the following 5-point scale and score was rated as 0 = clear (No signs of PSO; post-inflammatory hyperpigmentation may be present), 1 = almost clear (No thickening; normal to pink coloration; no to minimal focal scaling), 2 = mild (Just detectable to mild thickening; pink to light red coloration; predominately fine scaling), 3 = moderate (Clearly distinguishable to moderate thickening; dull to bright red, moderate scaling), and 4 = severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). The IGA response is defined as score of 0 (clear) or 1 (almost clear) with at least a 2-category improvement relative to Baseline.

Time frame:
Baseline, Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator Global Assessment (IGA) Response Defined as Score of 0 (Clear) or 1 (Almost Clear) AND at Least a 2-grade Reduction From Baseline at Week 4 in the Subset of Participants With Psoriatic Skin Lesions at Baseline
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Percentage of Participants With Investigator Global Assessment (IGA) Response Defined as Score of 0 (Clear) or 1 (Almost Clear) AND at Least a 2-grade Reduction From Baseline at Week 4 in the Subset of Participants With Psoriatic Skin Lesions at Baseline3.928.911.3
SecondaryPercentage of Participants With an IGA Response Defined as Score of 0 (Clear) or 1 (Almost Clear) AND at Least a 2-grade Reduction From Baseline at Week 16 in the Subset of Participants With Psoriatic Skin Lesions at Baseline

IGA measured the overall severity of PSO using the following 5-point scale and score was rated as 0 = clear (No signs of PSO; post-inflammatory hyperpigmentation may be present), 1 = almost clear (No thickening; normal to pink coloration; no to minimal focal scaling), 2 = mild (Just detectable to mild thickening; pink to light red coloration; predominately fine scaling), 3 = moderate (Clearly distinguishable to moderate thickening; dull to bright red, moderate scaling), and 4 = severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). The IGA response is defined as score of 0 (clear) or 1 (almost clear) with at least a 2-category improvement relative to Baseline.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Response Defined as Score of 0 (Clear) or 1 (Almost Clear) AND at Least a 2-grade Reduction From Baseline at Week 16 in the Subset of Participants With Psoriatic Skin Lesions at Baseline
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Percentage of Participants With an IGA Response Defined as Score of 0 (Clear) or 1 (Almost Clear) AND at Least a 2-grade Reduction From Baseline at Week 16 in the Subset of Participants With Psoriatic Skin Lesions at Baseline3.950.533.9
SecondaryChange From Baseline in the Patient's Assessment of Arthritis Pain (PtAAP) at Week 16

The PtAAP VAS is part of the American College of Rheumatology core set of measures in arthritis. Participants assessed their arthritis pain using a VAS ranging from 0 (no pain) to 100 (most severe pain). A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in the Patient's Assessment of Arthritis Pain (PtAAP) at Week 16
score on a scalePlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Change From Baseline in the Patient's Assessment of Arthritis Pain (PtAAP) at Week 16-6.3 ± 1.5-23.6 ± 1.3-25.7 ± 2.5
SecondaryPercentage of Participants With an Enthesitis-free State Based on the Spondyloarthritis Research Consortium of Canada (SPARCC) Index at Week 16 in the Subgroup of Participants With Enthesitis at Baseline

Presence of enthesitis was assessed in the subgroup of participants with enthesitis at Baseline. The SPARCC index measures the severity of enthesitis through the assessment of 16 sites, 8 for the right part and 8 for the left part of the body: the greater trochanter (right/left), quadriceps tendon insertion into the patella (right/left), patellar ligament insertion into the patella and tibial tuberosity (right/left), achilles tendon insertion (right/left), plantar fascia insertion (right/left), medial and lateral epicondyles (right/left), and the supraspinatus insertion (right/left). Tenderness on examination is recorded as either present (1) or absent (0) for each of the 16 sites, for an average range of 0 (no enthesitis) to 16 (severe enthesitis).

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Enthesitis-free State Based on the Spondyloarthritis Research Consortium of Canada (SPARCC) Index at Week 16 in the Subgroup of Participants With Enthesitis at Baseline
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Percentage of Participants With an Enthesitis-free State Based on the Spondyloarthritis Research Consortium of Canada (SPARCC) Index at Week 16 in the Subgroup of Participants With Enthesitis at Baseline35.650.052.3
SecondaryChange From Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Total Score at Week 16

The PsAID-12 is a patient-reported outcome measure for assessing the impact of Psoriatic Arthritis (PsA) in 12 physical and psychological domains, including pain, fatigue, skin problems, work and/or leisure activities, functional capacity, discomfort, sleep disturbance, coping, anxiety/fear/uncertainty, embarrassment and/or shame, social participation, and depression. Each domain is assessed with a single question using a 0 to 10 numerical rating scale. Each domain score was multiplied by a weighting factor and the results were then summed to provide the total score. The total score ranged from 0 to 10, with higher scores indicating a worse status. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Total Score at Week 16
score on a scalePlaceboBKZ 160 mg Q4WADA 40 mg Q2W
Change From Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Total Score at Week 16-0.53 ± 0.10-1.83 ± 0.09-2.14 ± 0.16
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs were defined as any AEs with an onset date on or after the date of first IMP administration and within 140 days after the final dose of IMP.

Time frame:
From Baseline until Safety Follow-Up (up to Week 72)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2WPlacebo/BKZ 160 mg Q4WBKZ 160 mg Q4W/BKZ 160 mg Q4WADA 40 mg Q2W/ADA 40 mg Q2W
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study49.559.659.370.572.068.4
SecondaryPercentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

A SAE is any untoward medical occurrence that at any dose: Results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization; is a congenital anomaly or birth defect; is an infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. TEAEs were defined as any AEs with an onset date on or after the date of first IMP administration and within 140 days after the final dose of IMP.

Time frame:
From Baseline until Safety Follow-Up (up to Week 72)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2WPlacebo/BKZ 160 mg Q4WBKZ 160 mg Q4W/BKZ 160 mg Q4WADA 40 mg Q2W/ADA 40 mg Q2W
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study1.11.91.45.95.66.6
SecondaryPercentage of Participants With TEAEs Leading to Withdrawal From IMP During the Study

An AE is any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs were defined as any AEs with an onset date on or after the date of first IMP administration and within 140 days after the final dose of IMP.

Time frame:
From Baseline until Safety Follow-Up (up to Week 72)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Withdrawal From IMP During the Study
percentage of participantsPlaceboBKZ 160 mg Q4WADA 40 mg Q2WPlacebo/BKZ 160 mg Q4WBKZ 160 mg Q4W/BKZ 160 mg Q4WADA 40 mg Q2W/ADA 40 mg Q2W
Percentage of Participants With TEAEs Leading to Withdrawal From IMP During the Study1.11.92.11.82.73.7

Adverse events

Collected over From Baseline until Safety Follow-Up (up to Week 72). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/281 (0%)3/281 (1.1%)34/281 (12.1%)
BKZ 160 mg Q4W0/431 (0%)8/431 (1.9%)77/431 (17.9%)
ADA 40 mg Q2W0/140 (0%)2/140 (1.4%)13/140 (9.3%)
Placebo/BKZ 160 mg Q4W1/271 (0.4%)16/271 (5.9%)54/271 (19.9%)
BKZ 160 mg Q4W/BKZ 160 mg Q4W0/414 (0%)23/414 (5.6%)82/414 (19.8%)
ADA 40 mg Q2W/ADA 40 mg Q2W0/136 (0%)9/136 (6.6%)15/136 (11%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventPlaceboBKZ 160 mg Q4WADA 40 mg Q2WPlacebo/BKZ 160 mg Q4WBKZ 160 mg Q4W/BKZ 160 mg Q4WADA 40 mg Q2W/ADA 40 mg Q2W
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2810/4310/1400/2710/4142/136
GoitreEndocrine disorders0/2810/4310/1400/2710/4141/136
Non-alcoholic steatohepatitisHepatobiliary disorders0/2810/4310/1400/2710/4141/136
Otitis mediaInfections and infestations0/2810/4310/1400/2710/4141/136
Atypical pneumoniaInfections and infestations0/2810/4310/1400/2710/4141/136
Radius fractureInjury, poisoning and procedural complications0/2810/4310/1400/2710/4141/136
HaemarthrosisMusculoskeletal and connective tissue disorders0/2810/4310/1400/2710/4141/136
ChondropathyMusculoskeletal and connective tissue disorders0/2810/4310/1400/2710/4141/136
AsthmaRespiratory, thoracic and mediastinal disorders0/2810/4310/1400/2710/4141/136
Herpes zosterInfections and infestations0/2810/4311/1400/2710/4140/136
Most frequent other events
Most frequent other events
EventPlaceboBKZ 160 mg Q4WADA 40 mg Q2WPlacebo/BKZ 160 mg Q4WBKZ 160 mg Q4W/BKZ 160 mg Q4WADA 40 mg Q2W/ADA 40 mg Q2W
NasopharyngitisInfections and infestations13/28140/4317/14023/27129/4146/136
Upper respiratory tract infectionInfections and infestations18/28122/4313/14012/27120/4145/136
Urinary tract infectionInfections and infestations4/2819/4313/14015/27120/4143/136
Oral candidiasisInfections and infestations0/2819/4310/14014/27119/4141/136

Baseline characteristics

Baseline Characteristics refer to the RS which consists of enrolled participants that have been randomized.

Age, Categorical
Age, Categorical(Participants)PlaceboBKZ 160 mg Q4WADA 40 mg Q2WTotal
<=18 years0000
Between 18 and 65 years255386122763
>=65 years26451889
Age, Continuous
Age, Continuous(Years)PlaceboBKZ 160 mg Q4WADA 40 mg Q2WTotal
Mean48.7 ± 11.748.5 ± 12.649.0 ± 12.848.7 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBKZ 160 mg Q4WADA 40 mg Q2WTotal
Female15423069453
Male12720171399
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBKZ 160 mg Q4WADA 40 mg Q2WTotal
American Indian/Alaskan native0101
Asian717428
Black0112
White270410133813
Other/mixed4105
Missing0123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBKZ 160 mg Q4WADA 40 mg Q2WTotal
Hispanic or Latino54211
Not Hispanic or Latino276426136838
Missing0123
08

Study locations

136 sites
  • Pa0010 50017
    Phoenix, Arizona 85037, United States
  • Pa0010 50035
    San Diego, California 92025, United States
  • Pa0010 50004
    Tustin, California 92780, United States
  • Pa0010 50033
    Palm Harbor, Florida 34684, United States
  • Pa0010 50037
    Tampa, Florida 33613, United States
  • Pa0010 50039
    Atlanta, Georgia 30342, United States
  • Pa0010 50028
    Lexington, Kentucky 40504, United States
  • Pa0010 50015
    Hagerstown, Maryland 21742, United States
  • Pa0010 50016
    St Louis, Missouri 63141, United States
  • Pa0010 50029
    Albuquerque, New Mexico 87102, United States
  • Pa0010 50010
    Brooklyn, New York 11201, United States
  • Pa0010 50125
    Charlotte, North Carolina 28210, United States
  • Pa0010 50040
    Dayton, Ohio 45417, United States
  • Pa0010 50020
    Duncansville, Pennsylvania 16635, United States
  • Pa0010 50006
    Wyomissing, Pennsylvania 19610, United States
  • Pa0010 50008
    Johnston, Rhode Island 02919, United States
  • Pa0010 50007
    Orangeburg, South Carolina 29118, United States
  • Pa0010 50001
    Jackson, Tennessee 38305, United States
  • Pa0010 50012
    Memphis, Tennessee 38119, United States
  • Pa0010 50002
    Austin, Texas 78731, United States
  • Pa0010 50049
    Corpus Christi, Texas 78404, United States
  • Pa0010 50051
    Houston, Texas 77034, United States
  • Pa0010 50036
    Mesquite, Texas 75150, United States
  • Pa0010 50009
    Waco, Texas 76710, United States
  • Pa0010 50050
    Beckley, West Virginia 25801, United States
  • Pa0010 30005
    Camberwell, Australia
  • Pa0010 30002
    Clayton, Australia
  • Pa0010 30008
    Hobart, Australia
  • Pa0010 30003
    Maroochydore, Australia
  • Pa0010 30007
    Victoria Park, Australia
  • Pa0010 30006
    Woodville, Australia
  • Pa0010 40003
    Genk, Belgium
  • Pa0010 40002
    Leuven, Belgium
  • Pa0010 40059
    Mons, Belgium
  • Pa0010 50041
    Québec, Canada
  • Pa0010 50042
    Rimouski, Canada
  • Pa0010 50043
    Sidney, Canada
  • Pa0010 50044
    Trois-Rivières, Canada
  • Pa0010 40061
    Brno, Czechia
  • Pa0010 40065
    Brno, Czechia
  • Pa0010 40062
    Ostrava, Czechia
  • Pa0010 40009
    Pardubice, Czechia
  • Pa0010 40013
    Prague, Czechia
  • Pa0010 40014
    Prague, Czechia
  • Pa0010 40015
    Prague, Czechia
  • Pa0010 40063
    Prague, Czechia
  • Pa0010 40066
    Prague, Czechia
  • Pa0010 40010
    Uherské Hradiště, Czechia
  • Pa0010 40012
    Zlín, Czechia
  • Pa0010 40019
    Paris, France
  • Pa0010 40068
    Tours, France
  • Pa0010 40074
    Bad Doberan, Germany
  • Pa0010 40025
    Berlin, Germany
  • Pa0010 40028
    Berlin, Germany
  • Pa0010 40076
    Cottbus, Germany
  • Pa0010 40023
    Erlangen, Germany
  • Pa0010 40117
    Frankfurt, Germany
  • Pa0010 40029
    Hamburg, Germany
  • Pa0010 40071
    Hamburg, Germany
  • Pa0010 40027
    Herne, Germany
  • Pa0010 40078
    Leipzig, Germany
  • Pa0010 40348
    Magdeburg, Germany
  • Pa0010 40026
    Ratingen, Germany
  • Pa0010 40081
    Budapest, Hungary
  • Pa0010 40083
    Budapest, Hungary
  • Pa0010 40032
    Debrecen, Hungary
  • Pa0010 40030
    Eger, Hungary
  • Pa0010 40082
    Kistarcsa, Hungary
  • Pa0010 40079
    Szentes, Hungary
  • Pa0010 40033
    Székesfehérvár, Hungary
  • Pa0010 40080
    Szombathely, Hungary
  • Pa0010 40084
    Catania, Italy
  • Pa0010 40087
    Milan, Italy
  • Pa0010 40085
    Pisa, Italy
  • Pa0010 40086
    Reggio Emilia, Italy
  • Pa0010 20035
    Bunkyō City, Japan
  • Pa0010 20036
    Kawachi-Nagano-shi, Japan
  • Pa0010 20045
    Kita-ku, Japan
  • Pa0010 20049
    Kitakyushu, Japan
  • Pa0010 20044
    Minatoku, Japan
  • Pa0010 20033
    Nagoya, Japan
  • Pa0010 20041
    Osaka, Japan
  • Pa0010 20046
    Osaka, Japan
  • Pa0010 20048
    Saitama, Japan
  • Pa0010 20031
    Sapporo, Japan
  • Pa0010 20042
    Sasebo, Japan
  • Pa0010 20032
    Suita, Japan
  • Pa0010 20043
    tabashi City, Japan
  • Pa0010 20030
    Tokyo, Japan
  • Pa0010 40093
    Bialystok, Poland
  • Pa0010 40119
    Bydgoszcz, Poland
  • Pa0010 40038
    Elblag, Poland
  • Pa0010 40088
    Elblag, Poland
  • Pa0010 40096
    Gdynia, Poland
  • Pa0010 40042
    Krakow, Poland
  • Pa0010 40092
    Krakow, Poland
  • Pa0010 40037
    Lublin, Poland
  • Pa0010 40091
    Nowa Sól, Poland
  • Pa0010 40044
    Poznan, Poland
  • Pa0010 40090
    Poznan, Poland

Showing the first 100 of 136 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ritchlin CT, Coates LC, McInnes IB, Mease PJ, Merola JF, Tanaka Y, Asahina A, Gossec L, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Landewe RB. Bimekizumab treatment in biologic DMARD-naive patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023 Nov;82(11):1404-1414. doi: 10.1136/ard-2023-224431. Epub 2023 Sep 11. PubMed 37696588 ↗
  • Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, McInnes IB. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther. 2024 Jun;11(3):817-828. doi: 10.1007/s40744-024-00652-7. Epub 2024 Mar 6. PubMed 38446397 ↗
  • Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA. Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies. Ther Adv Musculoskelet Dis. 2024 Nov 11;16:1759720X241288071. doi: 10.1177/1759720X241288071. eCollection 2024. PubMed 39534481 ↗
  • Mease PJ, Merola JF, Tanaka Y, Gossec L, McInnes IB, Ritchlin CT, Landewe RBM, Asahina A, Ink B, Heinrichs A, Bajracharya R, Shende V, Coarse J, Coates LC. Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies. Rheumatol Ther. 2025 Aug;12(4):609-612. doi: 10.1007/s40744-025-00764-8. Epub 2025 May 10. PubMed 40347389 ↗
  • Thaci D, Asahina A, Boehncke WH, Gottlieb AB, Lebwohl M, Warren RB, Edens H, Ink B, Bajracharya R, Coarse J, Merola JF. Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year. Dermatol Ther (Heidelb). 2026 Feb;16(2):953-976. doi: 10.1007/s13555-025-01599-5. Epub 2025 Dec 12. PubMed 41381988 ↗
  • Gossec L, Coates LC, Landewe RBM, Mease PJ, Merola JF, Ritchlin CT, Tanaka Y, Asahina A, Proft F, Goldammer N, Manente M, Ink B, Bajracharya R, Coarse J, McInnes IB. Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies. Rheumatology (Oxford). 2026 May 5;65(5):keag118. doi: 10.1093/rheumatology/keag118. PubMed 41838419 ↗
  • Gossec L, Tillett W, Coates LC, Mease PJ, de Wit M, Gladman DD, Orbai AM, Proft F, Ink B, Bajracharya R, Lambert J, Healy P, Husni ME. Control of Inflammation and Sustained Improvements in Patient-Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two-Year Results From Two Phase 3 Studies. ACR Open Rheumatol. 2026 May;8(5):e90053. doi: 10.1002/acr2.90053. PubMed 42152504 ↗
  • Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Lambert J, Morup M, Boonen A, Walsh J. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. J Rheumatol. 2026 Aug 1:jrheum.2026-0104. doi: 10.3899/jrheum.2026-0104. Online ahead of print. PubMed 42386286 ↗
  • Mease PJ, Merola JF, Magrey M, Nash P, Poddubnyy D, Lebwohl M, Bajracharya R, Ink B, Marten A, Manente M, Peterson L, White K, Gensler LS. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies. RMD Open. 2026 Mar 10;12(1):e006174. doi: 10.1136/rmdopen-2025-006174. PubMed 41807031 ↗
  • Mease PJ, Gensler LS, Orbai AM, Warren RB, Bajracharya R, Ink B, Marten A, Massow U, Shende V, Manente M, Peterson L, White K, Landewe R, Poddubnyy D. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies. RMD Open. 2025 Apr 6;11(2):e005026. doi: 10.1136/rmdopen-2024-005026. PubMed 40194794 ↗
  • Gladman DD, Mease PJ, Gossec L, Husni ME, Gottlieb AB, Ink B, Bajracharya R, Coarse J, Lyris N, Lambert J, Tillett W. Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies. J Rheumatol. 2025 May 1;52(5):466-478. doi: 10.3899/jrheum.2024-0923. PubMed 39892885 ↗
  • Husni ME, Mease PJ, Merola JF, Tillett W, Goldammer N, Ink B, Coarse J, Lambert J, Taieb V, Gladman DD. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies. RMD Open. 2024 Sep 23;10(3):e004464. doi: 10.1136/rmdopen-2024-004464. PubMed 39313302 ↗
  • Mease PJ, Merola JF, Tanaka Y, Gossec L, McInnes IB, Ritchlin CT, Landewe RBM, Asahina A, Ink B, Heinrichs A, Bajracharya R, Shende V, Coarse J, Coates LC. Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies. Rheumatol Ther. 2024 Oct;11(5):1363-1382. doi: 10.1007/s40744-024-00708-8. Epub 2024 Aug 31. PubMed 39215949 ↗
  • Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, McInnes IB. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther. 2024 Oct;11(5):1403-1412. doi: 10.1007/s40744-024-00706-w. Epub 2024 Aug 9. PubMed 39120849 ↗
  • Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Taieb V, Eells J, McInnes IB. Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther. 2024 Oct;11(5):1413-1423. doi: 10.1007/s40744-024-00705-x. Epub 2024 Aug 9. PubMed 39120848 ↗
  • Gossec L, Orbai AM, de Wit M, Coates LC, Ogdie A, Ink B, Coarse J, Lambert J, Taieb V, Gladman DD. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies. Rheumatology (Oxford). 2024 Sep 1;63(9):2399-2410. doi: 10.1093/rheumatology/keae277. PubMed 38754125 ↗
  • Warren RB, McInnes IB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, Mease PJ. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther. 2024 Jun;11(3):829-839. doi: 10.1007/s40744-024-00659-0. Epub 2024 Mar 15. PubMed 38488975 ↗
  • Maloney A, Dua P, Ahmed GF. Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model-Based Meta-Analysis of American College of Rheumatology Response Criteria. Clin Pharmacol Ther. 2024 May;115(5):1007-1014. doi: 10.1002/cpt.3135. Epub 2024 Jan 12. PubMed 38073049 ↗
  • McInnes IB, Asahina A, Coates LC, Landewe R, Merola JF, Ritchlin CT, Tanaka Y, Gossec L, Gottlieb AB, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Mease PJ. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023 Jan 7;401(10370):25-37. doi: 10.1016/S0140-6736(22)02302-9. Epub 2022 Dec 6. PubMed 36493791 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Aug 2021, 28 months.

Results were first posted in Oct 2024, 3 years 2 months after primary completion. A results delay was requested in Aug 2022.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 28 months is close to that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Mar 29, 2019
StartActual
Apr 3, 2019
Primary completionActual
Aug 17, 2021
CompletionActual
Jul 11, 2022
Results delay requested
Aug 16, 2022
Results first posted
Oct 23, 2024
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
Results publication added: Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Lambert J, Mo… PubMed 42386286 ↗
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Publications Results publication added: Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Lambert J, Mo… PubMed 42386286 ↗
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03895203
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Mar 29, 2019
Start date
Apr 3, 2019
Primary completion
Aug 17, 2021
Completion
Jul 11, 2022
Results posted
Oct 23, 2024
Last update
Sep 28, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion